WASHINGTON, DC – The Center for Strategic and International Studies (CSIS), a bipartisan, nonprofit policy research organization dedicated to advancing practical ideas to address the world’s greatest ...
The Supreme Court on Tuesday dismissed appeals in the 2002 death case of actress Prathyusha, ruling out murder and affirming Gudipalli Siddhartha Reddy’s conviction for abetment of suicide. Reddy ...
In a significant ruling that brought closure to a 23-year-old legal tussle, the Supreme Court of India, on Tuesday dismissed the appeal filed by Gudipalli Siddhartha Reddy challenging his conviction ...
HYDERABAD, Feb 17 (Reuters) - Indian drugmaker Dr Reddy’s Laboratories (REDY.NS), opens new tab hopes to launch a generic version of Novo Nordisk’s (NOVOb.CO), opens new tab blockbuster weight‑loss ...
The Supreme Court on Tuesday (February 17) brought to a close one of the most protracted and emotionally charged legal battles in the Indian entertainment world by delivering its final judgment in the ...
HYDERABAD, Feb 17 (Reuters) - Indian drugmaker Dr Reddy's laboratories aims to launch a generic version of Novo Nordisk's blockbuster weight loss drug Wegovy, subject to approval, at a price ...
HYDERABAD, Jan 21 (Reuters) - Indian drugmaker Dr Reddy's (REDY.NS), opens new tab, which reported a smaller-than-expected fall in quarterly profit on Wednesday, said that it has received an approval ...
Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key ...
What are music’s biggest global artist stories of 2025? Here’s a trio for you: Taylor Swift’s record-shattering The Life Of A Showgirl; Bad Bunny’s culture-defining residency in Puerto Rico (and ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min AAR's $78M acquisition of HAECO ...
Dr. Reddy’s Laboratories remains a compelling buy due to underappreciated growth in biosimilars and GLP-1 segments, despite near-term headwinds. RDY's Q2 FY26 results showed modest revenue growth, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results